Bigelow Investment Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD

18 Sep 2025, 10:46 by Amy Steele · The Cerbat Gem

Bigelow Investment Advisors LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 5,018 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. Bigelow Investment Advisors LLC’s holdings in Gilead Sciences were worth $556,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in GILD. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences in the first quarter worth about $620,415,000. Finally, National Pension Service increased its holdings in shares of Gilead Sciences by 6.9% in the first quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company’s stock worth $389,191,000 after purchasing an additional 223,171 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 1.3%

Shares of NASDAQ GILD opened at $112.26 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $139.29 billion, a price-to-earnings ratio of 22.36, a PEG ratio of 0.75 and a beta of 0.36. The stock has a 50 day moving average price of $114.03 and a 200 day moving average price of $110.08. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on GILD shares. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. UBS Group boosted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. Finally, Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Read Our Latest Analysis on GILD

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,390,030 over the last 90 days. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

(Free Report)